Integra LifeSciences I Ltd. v. Merck KGaA
Preclinical research that is not included in an FDA submission can be exempt from patent infringement under 35 U.S.C. § 271(e)(1) if the drug maker has a reasonable basis for believing that the research, if successful, would be appropriate to include in an FDA submission.